Partnership effort leverages AI to help detect disease progression in multiple sclerosis
An ongoing study involving Novartis Pharmaceuticals Canada Inc. (Novartis Canada) and Montreal-based digital biomarker and AI company Innodem Neurosciences illustrates the important role that combined scientific efforts play in addressing complex diseases.
According to a March 25, 2024 press release, an ongoing longitudinal observational trial supported by Novartis Canada, which involves Innodem’s ETNA-MS technology, is investigating the potential utility of biomarkers to monitor MS disease status.
MS progression is typically assessed using magnetic resonance imaging technology, which focuses on new or growing brain lesions. Innodem’s Eye Tracking Neurological Assessment for Multiple Sclerosis (ETNA-MS) technology turns an iPad Pro into a medical device capable of capturing eye movements that can indicate subtle changes of disease progression.